Memo Therapeutics (private company)

Memo Therapeutics AG develops solutions for antibody discovery and immune repertoire analysis. The company's platform, DROPZYLLA, creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library.

The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies.